The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
Subscribe To Our Newsletter & Stay Updated
